Literature DB >> 19604458

Tyrosine kinase inhibitors in systemic sclerosis: the case for imatinib.

Flavia V Castelino1, Swati Bhattacharyya, John Varga.   

Abstract

Entities:  

Year:  2009        PMID: 19604458     DOI: 10.1007/s11926-009-0032-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  8 in total

1.  Imatinib for the treatment of refractory, diffuse systemic sclerosis.

Authors:  P P Sfikakis; V G Gorgoulis; C G Katsiari; K Evangelou; C Kostopoulos; C M Black
Journal:  Rheumatology (Oxford)       Date:  2008-03-07       Impact factor: 7.580

2.  Is imatinib mesylate a promising drug in systemic sclerosis?

Authors:  P L A van Daele; W A Dik; H B Thio; P Th W van Hal; J A M van Laar; H Hooijkaas; P M van Hagen
Journal:  Arthritis Rheum       Date:  2008-08

3.  Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

Authors:  Jörg H W Distler; Astrid Jüngel; Lars C Huber; Ursula Schulze-Horsel; Jochen Zwerina; Renate E Gay; Beat A Michel; Thomas Hauser; Georg Schett; Steffen Gay; Oliver Distler
Journal:  Arthritis Rheum       Date:  2007-01

4.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.

Authors:  Craig E Daniels; Mark C Wilkes; Maryanne Edens; Ted J Kottom; Stephen J Murphy; Andrew H Limper; Edward B Leof
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

5.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

6.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Authors:  Risto Kerkelä; Luanda Grazette; Rinat Yacobi; Cezar Iliescu; Richard Patten; Cara Beahm; Brian Walters; Sergei Shevtsov; Stéphanie Pesant; Fred J Clubb; Anthony Rosenzweig; Robert N Salomon; Richard A Van Etten; Joseph Alroy; Jean-Bernard Durand; Thomas Force
Journal:  Nat Med       Date:  2006-07-23       Impact factor: 53.440

7.  Molecular framework for response to imatinib mesylate in systemic sclerosis.

Authors:  Lorinda Chung; David F Fiorentino; Maya J Benbarak; Adam S Adler; Melissa M Mariano; Ricardo T Paniagua; Ausra Milano; M Kari Connolly; Boris D Ratiner; Robert L Wiskocil; Michael L Whitfield; Howard Y Chang; William H Robinson
Journal:  Arthritis Rheum       Date:  2009-02

8.  A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate.

Authors:  S Bhattacharyya; W Ishida; M Wu; M Wilkes; Y Mori; M Hinchcliff; E Leof; J Varga
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.